Afimmune   Report issue

For profit Phase 2
Founded: Dublin Ireland (2016)

Organization Overview

First Clinical Trial
2016
NCT02941549
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Afimmune